LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

Home・Elenco Azioni・Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

37.49 1.65

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

36.04

Massimo

Metriche Chiave
By Trading Economics
Entrata	7.3M -123M
Vendite	3.7M 3.9M
EPS	-1.29
Margine di Profitto	-3,161.261
Dipendenti	594
EBITDA	20M -122M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+132.32% upside

Dividendi
By Dow Jones
Utili prossimi	6 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-140M 4.3B
Apertura precedente	35.84
Chiusura precedente	37.49

Notizie sul Sentiment di mercato

By Acuity

58%

42%

280 / 346 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

30.39 / 33.46 Supporto e resistenza

Crinetics Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

12 mag 2026, 22:50 UTC

Utili

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

12 mag 2026, 22:49 UTC

Utili

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

12 mag 2026, 22:32 UTC

Utili

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

12 mag 2026, 23:48 UTC

Discorsi di Mercato

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

12 mag 2026, 22:57 UTC

Discorsi di Mercato

Utili

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

12 mag 2026, 22:26 UTC

Utili

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

12 mag 2026, 22:25 UTC

Utili

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

12 mag 2026, 22:25 UTC

Utili

Aristocrat Leisure Interim Dividend A$0.50/Security

12 mag 2026, 22:24 UTC

Utili

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

12 mag 2026, 22:23 UTC

Utili

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

12 mag 2026, 22:23 UTC

Utili

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

12 mag 2026, 22:19 UTC

Utili

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

12 mag 2026, 22:14 UTC

Utili

CBA: Business Lending Continued to Grow Above System>CBA.AU

12 mag 2026, 22:14 UTC

Utili

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

12 mag 2026, 22:13 UTC

Utili

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

12 mag 2026, 22:12 UTC

Utili

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

12 mag 2026, 22:12 UTC

Utili

CBA 3Q New Home Loan Funding A$45B>CBA.AU

12 mag 2026, 22:11 UTC

Utili

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

12 mag 2026, 22:11 UTC

Utili

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

12 mag 2026, 22:10 UTC

Utili

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

12 mag 2026, 22:09 UTC

Utili

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

12 mag 2026, 22:09 UTC

Utili

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

12 mag 2026, 22:08 UTC

Utili

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

12 mag 2026, 22:07 UTC

Utili

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

12 mag 2026, 22:06 UTC

Utili

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

12 mag 2026, 22:06 UTC

Utili

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

12 mag 2026, 22:05 UTC

Utili

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

12 mag 2026, 22:04 UTC

Utili

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

12 mag 2026, 22:04 UTC

Utili

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

12 mag 2026, 22:04 UTC

Utili

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Confronto tra pari

Modifica del prezzo

Crinetics Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

132.32% in crescita

Previsioni per 12 mesi

Media 85.75 USD 132.32%

Alto 97 USD

Basso 67 USD

Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

9 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 9 che hanno fornito valutazioni azionarie a Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

30.39 / 33.46Supporto e resistenza

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

280 / 346 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.